Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT06533579
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 · United States · 11 sites
Registry update: 26 Oct 2026
NCT06757647
Recruiting
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 · United States · 1 site
Registry update: 16 Dec 2025
NCT06876649
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Phase 4 · Australia, France, United Kingdom, Italy, Japan, South Korea, Poland, United States · 36 sites
Registry update: 2 Mar 2026
NCT06876662
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Phase 4 · Australia, France, United Kingdom, Italy, Japan, South Korea, Poland, United States · 35 sites
Registry update: 2 Mar 2026
NCT06849713
Recruiting
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Phase 2 · United States · 2 sites
Registry update: 11 Aug 2026
NCT06812715
Recruiting
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2 · Australia · 3 sites
Registry update: 3 Sept 2026
NCT06548152
Recruiting
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
Not applicable · France · 1 site
Registry update: 27 Oct 2026
NCT06815003
Recruiting
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Phase 2 · United States · 1 site
Registry update: 29 Jun 2026
NCT06961669
Recruiting
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
Not applicable · China · 1 site
Registry update: 29 May 2025
NCT06846671
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Phase 3 · Argentina, Australia, Brazil, Canada, Czechia, Germany, United Kingdom, Italy, Japan, South Korea, Netherlands, Poland, United States · 132 sites
Registry update: 28 Sept 2026
2024-512019-36-00
Recruiting
A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors
Phase 1 · Germany · 3 sites
Registry update: 13 Apr 2026
NCT06708897
Recruiting
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Phase 1 · United States · 5 sites
Registry update: 31 Jul 2026
NCT06980116
Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · Spain, France, United Kingdom, Georgia, Greece, Moldova, Poland, Romania, Ukraine · 22 sites
Registry update: 13 Aug 2026
NCT06644183
Recruiting
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 · United States · 1 site
Registry update: 11 Feb 2026
NCT05025774
Recruiting
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Not applicable · United States · 1 site
Registry update: 24 Nov 2025
NCT06528301
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Phase 1 · Australia, United States · 9 sites
Registry update: 15 Oct 2026
NCT06784167
Recruiting
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Not applicable · United States · 1 site
Registry update: 23 Sept 2026
NCT06651970
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Phase 4 · Czechia, Spain, United Kingdom, Italy, Poland, United States · 22 sites
Registry update: 24 Sept 2026
NCT06788639
Recruiting
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Not applicable · United States · 1 site
Registry update: 24 Feb 2025
NCT06821880
Recruiting
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
Not applicable · Austria, Germany · 5 sites
Registry update: 12 Feb 2025

Ordered by registry start date. Freshness and sponsorship never change the order.